Cargando…

The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance

BACKGROUND: Nowadays, the incidence rate of advanced and metastatic prostate cancer at the first time of diagnosis grows higher in China yearly. At present, androgen deprivation therapy (ADT) is the primary treatment of advanced prostate cancer. However, after several years of ADT, most patients wil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ao, Gao, Yi, Wang, Qi, Lin, Wenhao, Ma, Zhiyang, Yang, Xiaoqun, Chen, Lu, Xu, Danfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510184/ https://www.ncbi.nlm.nih.gov/pubmed/37726835 http://dx.doi.org/10.1186/s12967-023-04320-2

Ejemplares similares

Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis
por: Zhang, Wenhui, et al.
Publicado: (2021)

Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
por: Beltran, Himisha, et al.
Publicado: (2016)

Comment on: Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis by Jing Li et al.
por: Wilkinson, Scott, et al.
Publicado: (2022)

A Combined Technology to Protect the Anatomic Integrity of Distal Urethral Sphincter Complex in Radical Prostatectomy Improves Early Urinary Continence Recovery Without Sacrifice of Oncological Outcomes
por: Liu, Ao, et al.
Publicado: (2021)

Genetic heterogeneity and clonal evolution in neuroblastoma
por: Mora, J, et al.
Publicado: (2001)

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
por: Bianchi, Giada, et al.
Publicado: (2014)

Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients
por: Pölsterl, Sebastian, et al.
Publicado: (2017)

Intratumoral heterogeneity and clonal evolution in liver cancer
por: Losic, Bojan, et al.
Publicado: (2020)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration
por: Akagi, Keiko, et al.
Publicado: (2023)

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
por: Greasley, Rosa, et al.
Publicado: (2015)

Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer
por: Wang, Keshan, et al.
Publicado: (2018)

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
por: Di Nunno, Vincenzo, et al.
Publicado: (2018)

Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Naseer, Faiza, et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Genome-wide Expression Analysis Identifies the Association between SEC14L2 and Castration-resistant Prostate Cancer Survival
por: Liu, Shiyun, et al.
Publicado: (2021)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Targeting hexokinase 2 in castration-resistant prostate cancer
por: Deng, Yibin, et al.
Publicado: (2015)

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer
por: Mao, Yifeng, et al.
Publicado: (2022)

Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors
por: Varela, Ignacio, et al.
Publicado: (2017)

EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation
por: Huang, Hai, et al.
Publicado: (2019)

Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
por: Chen, Jiaxian, et al.
Publicado: (2022)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

Peri-prostatic Fat Volume Measurement as a Predictive Tool for Castration Resistance in Advanced Prostate Cancer
por: Salji, Mark, et al.
Publicado: (2018)

Genomic Heterogeneity and Clonal Evolution in Gastroesophageal Junction Cancer Revealed by Single Cell DNA Sequencing
por: Duan, Qingke, et al.
Publicado: (2021)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
por: Qu, Yuanyuan, et al.
Publicado: (2015)

Unmasking Intra-Tumoral Heterogeneity and Clonal Evolution in NF1-MPNST
por: Moon, Chang-In, et al.
Publicado: (2020)

Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression
por: Mota, Alba, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pgbkp4vjv0loccr5k7f1rlq5dr